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INTRODUCTION
Chronic hepatitis B virus (HBV) infection is a worldwide
health problem affecting an estimated 350 million individuals
in the world, and is a leading cause of cirrhosis and hepatocellu-
lar carcinoma in Asian countries (1, 2). The therapeutic goal
in patients with chronic HBV infection is to limit or to reverse
the progression of the disease through sustained suppression
of HBV replication (3).
Lamivudine, an oral nucleoside analogue, potentially inhibits
HBV replication by interfering with HBV DNA polymerase
and results in serum alanine aminotransferase (ALT) level nor-
malisation, hepatitis B e antigen (HBeAg) seroconversion en-
hancement and liver histology improvement (3-11). However,
these effects are not sustained in a significant proportion of
patients due to the development of drug resistance, which is
mediated largely by point mutations at the YMDD motif of
the HBV DNA polymerase gene. By the end of one year of
lamivudine therapy, 15 to 20% of patients have resistant HBV
variants in the circulation; the figures rises to 67% by the
fourth year (12, 13). Follow-up studies on continued lamivu-
dine therapy after the emergence of YMDD mutation showed
that acute exacerbation of hepatitis with hepatic decompen-
sation may occur (13-15). Moreover, even fatal hepatic fail-
ure cases by lamivudine-resistant HBV during lamivudine
therapy have been reported (16, 17).
Orthotopic liver transplantation can be an option for patients
with hepatic decompensation by lamivudine-resistant HBV.
However, patients with high serum levels of lamivudine-resis-
tant HBV DNA may be unable to undergo liver transplanta-
tion, as they are at high risk for recurrent HBV infection in the
liver graft besides an inadequate supply of donor livers (18).
Consequently, there is a clear need for a safe and effective treat-
ment regimen for patients with decompensated liver disease
by lamivudine-resistant HBV.
Adefovir dipivoxil is an oral prodrug of an acyclic monophos-
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Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine
in Patients with Decompensated Liver Disease and Lamivudine-resis-
tant Hepatitis B Virus
The purpose of this prospective study was to evaluate the efficacy and safety of ade-
fovir dipivoxil with or without ongoing lamivudine in decompensated lamivudine-resis-
tant chronic hepatitis B patients. Forty-six hepatitis B e antigen (HBeAg)-positive pa-
tients with decompensated liver function and lamivudine-resistant hepatitis B virus
(HBV) were assigned to adefovir dipivoxil monotherapy (n=18) or combination therapy
with ongoing lamivudine (n=28) according to their own preference. After 24 weeks
of treatment, 83% of monotherapy and 86% of combination therapy showed serum
HBV DNA below detection limit (<0.5 pg/mL). Alanine aminotransferase (ALT) normal-
ized in 78% and 82% respectively. Median Child-Pugh-Turcotte (CPT) score or Model
for End-Stage Liver Disease (MELD) score reduced significantly by 3 or 5 point in
monotherapy and 2 or 2 point in combination therapy respectively. There were no
significant differences in rate of undetectable serum HBV DNA, median change of
ALT and median reduction of CPT or MELD scores between the two groups. In con-
clusion, both adefovir dipivoxil monotherapy and combination therapy with ongoing
lamivudine result in comparable virologic, biochemical, and clinical improvements
in HBeAg-positive patients with decompensated liver function and lamivudine-resistant
HBV. Combination with lamivudine showed no additional benefit over monotherapy
during 24 weeks of treatment in these patients.
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phate adenine analog, which is a selective inhibitor of DNA
polymerase and reverse transcriptase of HBV and has been
shown to suppress potently both lamivudine-resistant and
wild-type HBV (19-21). A randomized controlled study in
patients with compensated liver disease and lamivudine-resis-
tant HBV showed that adefovir dipivoxil was potent in sup-
pression of lamivudine-resistant HBV replication, while lami-
vudine provided little or no additional benefit in combination
therapy (21). However, in patients with hepatic decompensa-
tion and lamivudine-resistant HBV, the clinical benefit and
safety of adefovir dipivoxil monotherapy compared to adefovir
dipivoxil/lamivudine combination therapy has not been report-
ed in controlled trials so far. Two separate uncontrolled studies
showed that addition of adefovir dipivoxil to ongoing lamivu-
dine decreased HBV DNA levels and improved biochemical
markers (22, 23). However, they did not evaluate the effects
of switching from lamivudine to adefovir dipivoxil monother-
apy. Moreover, in another study, adefovir dipivoxil was reported
to be associated with deterioration of renal function in patients
with recurrent hepatitis B after liver transplantation or with
decompensated hepatitis B in need of transplantation (24).
We performed this prospective, open-labeled, controlled
study to evaluate the efficacy and safety of adefovir dipivoxil
monotherapy and adefovir dipivoxil/lamivudine combina-
tion therapy in patients with decompensated liver disease
and lamivudine-resistant HBV.
MATERIALS AND METHODS
Inclusion/exclusion criteria
Patients eligible for the study were 18-67 yr of age with
serum hepatitis B surface antigen (HBsAg) for at least 6 mon-
th, positive for HBeAg, and had an elevated serum ALT levels
>1.3 times upper limit of normal (ULN) on at least two occa-
sions at least two months apart and decompensated hepatic
function. All patients had received lamivudine treatment for
at least 6 months that was ongoing at the time of screening
and had serum HBV DNA level ≥2.5 pg/mL, as measured
by Digene Hybrid Capture II assay (Digene Corporation, Gai-
thersburg, MD, U.S.A.). Decompensation of hepatic function
was defined as the presence of one or more of the followings:
1) serum bilirubin level >two times ULN without other caus-
es; 2) prothrombin time >3 sec prolonged; 3) serum albumin
level <3.2 g/dL; 4) a history of ascites, variceal hemorrhage,
or hepatic encephalopathy; 5) Child-Pugh-Turcotte (CPT)
score ≥7 (23).
Patients were excluded from the study if they were HBeAg-
negative or coinfected with hepatitis C virus, hepatitis delta
virus or human immunodeficiency virus, or had prior use of
adefovir dipivoxil or other drugs with activity against HBV
within the 12 months preceding study screening. Patients
were also excluded if they had a documented hepatocellular
carcinoma, screening calculated creatinine clearance <50 mL/
min, or serum creatinine level >1.5 mg/dL. The majority of
patients were not candidates for liver transplantation because of
social, economic and/or medical problems.
All patients and their relatives signed the informed consent
form before enrollment. The study protocol was in accordance
with the ethical guidelines of the 1975 Declaration of Helsinki
and was approved by the Investigation and Ethics Commit-
tee for Human Research (protocol No ADF20001) at Asan
Medical Centre.
Study protocol
From June 2003 to February 2004, 52 consecutive patients
were recruited at screening. Two of the 52 patients were ex-
cluded from the study because they had transplantation within
two months of adefovir dipivoxil/lamivudine combination
therapy. 3 patients with HBeAg-negative hepatitis B were
also excluded from the study. One patient died of rapid pro-
gression of hepatic failure before the administration of adefovir
dipivoxil. At baseline, the remaining 46 patients were assigned
to switch from previous lamivudine monotherapy to either
adefovir dipivoxil 10 mg once daily (n=18) or combination
therapy with adefovir dipivoxil 10 mg once daily plus lamivu-
dine 100 mg once daily (n=28) for 24 weeks. The assignment
was made according to the patient’s own preference for eco-
nomic reasons. All patients were hospitalized before enroll-
ment for close monitoring and subsequently followed up in
outpatient clinic of our hospital. Serum biochemical test re-
sults, CPT score, Model for End-Stage Liver Disease (MELD)
score, HBeAg, anti-HBe, and serum HBV DNA levels were
recorded every eight weeks. The therapeutic efficacy was mea-
sured by the change of CPT or MELD score, serum HBV
DNA levels and serum biochemical test results. Virologic re-
sponse was defined as the loss of previously detectable serum
HBV DNA.
Baseline characteristics of the patients
Baseline characteristics including age, sex, duration of prior
lamivudine treatment, ALT level, total bilirubin level, CPT
score, MELD score, and HBV DNA level were not statistically
different between the two groups, although total bilirubin
level and MELD score tended to be higher in patients receiving
adefovir dipivoxil monotherapy than those receiving combi-
nation therapy (p=0.159 for total bilirubin level, p=0.083 for
MELD score) (Table 1). All patients had normal serum crea-
tinine levels and were hemodynamically stable at baseline.
Genotypic analysis for YMDD mutations
A MALDI-TOF mass spectrometry-based genotyping assay,
termed Restriction Fragment Mass Polymorphism (RFMP),
was performed to detect hepatitis B virus mutations that conferresistance to lamivudine as previously described (25). This
technique has been shown to be superior to DNA sequencing,
as it is able to detect HBV mutations that confer resistance to
lamivudine in the presence of wild-type virus background
and is sensitive to a lower limit of 100 copies of HBV DNA/
mL (25, 26). Blood samples to confirm the gene mutation
within the YMDD motif were available in 24 of the 46 pa-
tients, and all patients with available samples had YMDD
mutant HBV.
Statistical analysis
The associations of categorical variables such as sex, HBeAg
loss or HBeAg seroconversion between the two groups were
evaluated using Fisher’s exact test. Continuous variables such as
ALT level, total bilirubin level, HBV DNA level, age, CPT
score, and MELD score between the two groups were com-
pared using Wilcoxon rank sum test. The Wilcoxon signed
rank test was used to compare changes of the paired data in
each group. The correlation between baseline ALT level and
change of CPT or MELD score after 24 weeks of treatment
was analyzed using Spearman’s rank correlation. p-values of
less than 0.05 were considered to be statistically significant.
The analysis software was Statistical Package for the Social
Sciences, version 11.0 (SPSS Inc., Chicago, IL, U.S.A.).
RESULTS
Virologic response
The median serum HBV DNA levels decreased rapidly and
remained low during the 24 weeks of treatment in both groups
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Data are expressed as median (range) without specific notation.
ALT, alanine aminotransferase; ULN, upper limit of normal; CPT, Child-
Pugh-Turcotte; MELD, Model for End-Stage Liver Disease; HBV, hep-
atitis B virus.
Adefovir dipivoxil Combination 
monotherapy (n=18) therapy (n=28)
Age (yr) 48 (39-62) 46 (18-67) 0.218
Sex (male:female) 13:5 23:5 0.480
Prior lamivudine  35.5 (9-73) 30.5 (8-78) 0.848
duration (months)
ALT (IU/L) 178 (57-1143) 229 (55-1168) 0.804
<2×ULN, n (%) 4 (22) 5 (18)
2-5×ULN, n (%) 6 (33) 8 (28)
>5×ULN, n (%) 8 (45) 15 (54)
Total bilirubin (mg/dL) 3.5 (1.2-14.5) 2.8 (1.0-15.0) 0.159
Albumin (mg/dL) 2.6 (1.8-3.4) 2.8 (1.9-3.9) 0.219
CPT score 10 (7-12) 9 (7-12) 0.237
MELD score 16 (6-22) 12 (8-25) 0.083
HBV DNA (pg/mL) 100 (8-2442) 93 (17-2562) 0.822
Serum creatinine (mg/dL) 0.8 (0.5-1.3) 0.8 (0.4-1.1) 0.640
Table 1. Baseline characteristics of the patients
p
*adefovir dipivoxil monotherapy group; 
� combination therapy group
with adefovir dipivoxil/lamivudine.
1* Female/52 165 1.1 112 46 11 (15) 11 (21)
2* Male/52 50.3 9.5 57 51 11 (18) 12 (23)
3* Male/49 456.5 0.6 582 36 8 (10) 6 (6)
4
� Male/50 100 6.9 258 25 8 (10) 6 (9)
5
� Male/47 16.6 6.6 64 22 11 (17) 9 (14)
6
� Male/44 388.3 3.6 108 31 9 (11) 10 (13)
7
� Male/46 899.5 1.3 96 27 9 (11) 8 (11)
Table 2. Changes in serum HBV DNA levels, serum ALT levels
and CPT (MELD) scores in patients who had detectable serum
HBV DNA levels at week 24
Case
HBV DNA
(pg/mL)
Week
24
Base-
line
Sex/Age
(yr)
CPT (MELD) 
score
Week
24
Base-
line
ALT
(IU/L)
Week
24
Base-
line
Fig. 1. Median values of HBV DNA levels in adefovir dipivoxil monotherapy and adefovir dipivoxil/lamivudine combination therapy group
over 24 weeks of treatment. Median serum HBV DNA levels decreased rapidly within 8 weeks and remained low throughout the 24
weeks in both groups. The 0 marker on Y axis more accurately represents a value of <0.5 pg/mL HBV DNA because the lower limit of
detection of Digene Hybrid Capture II assay used for measurement of HBV DNA was 0.5 pg/mL. The horizontal lines in the box mark the
25th, 50th, and 75th percentiles of the data. Error bars extend from the quartiles to the farthest observation.
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(Fig. 1). At week 8, 10 (56%) of 18 patients in adefovir di-
pivoxil monotherapy group and 19 (68%) of 28 patients in
combination therapy group had serum HBV DNA level below
detection limit (<0.5 pg/mL) and the number of the patients
with undetectable serum HBV DNA level increased to 15
(83%) and 24 (86%) in each group at week 24. Even in 7 pa-
tients who had detectable serum HBV DNA levels at week
24 in both groups, HBV DNA levels were much lower at
week 24 than baseline (Table 2). There was no significant dif-
ference in the rate of undetectable serum HBV DNA between
the two groups (p=1.000).
Loss of HBeAg occurred in 4 (22%) patients in adefovir dip-
ivoxil monotherapy group and 8 (28%) in combination thera-
py group at week 24. HBeAg seroconversion (HBeAg neg-
ative and anti-HBe positive) occurred in 3 (17%) and 6 (21%)
patients in each group respectively. However, there was no sig-
nificant difference in the rate of HBeAg loss or HBeAg sero-
conversion between the two groups (p=1.000 in both com-
parisons).
Biochemical response
The median serum ALT levels in both groups decreased ra-
pidly and remained lower than the baseline levels throughout
the 24-week period (Fig. 2). Median reductions in serum ALT
levels were 145 IU/L in adefovir dipivoxil monotherapy group
and 197 IU/L in combination therapy group at week 24 (Table
3). There was no significant difference in median reduction
of serum ALT levels between the two groups (p=0.778). 7
(39%) patients in adefovir dipivoxil monotherapy group and
13 (46%) in combination therapy group had normal serum
ALT levels at week 8, and 14 (78%) and 23 (82%) patients
at week 24 respectively.
The median total bilirubin levels decreased significantly
from 3.5 at baseline to 1.7 mg/dL at week 24 in adefovir dip-
ivoxil monotherapy group (p=0.026) and from 2.8 to 1.6
mg/dL in combination therapy group (p=0.000). Although
the median reduction of total bilirubin levels was 1.7 or 1.1
mg/dL in each group respectively (Table 3), there was no signif-
icant difference in the median reduction of total bilirubin levels
between the two groups (p=0.581).
Clinical assessment of hepatic function
The median CPT score decreased from 10 at baseline to 7
at week 24 in adefovir dipivoxil monotherapy group and from
9 to 7 in combination therapy group. The reduction of CPT
score from baseline to week 24 in each group was significant
Fig. 2. Median values of ALT levels in adefovir dipivoxil monotherapy and adefovir dipivoxil/lamivudine combination therapy group over
24 weeks of treatment. Median ALT levels decreased rapidly within 8 weeks and remained lower than the baseline levels throughout the
24 weeks in both groups. The horizontal lines in the box mark the 25th, 50th, and 75th percentiles of the data. Error bars extend from the
quartiles to the farthest observation.
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Data are expressed as median (range) without specific notation.
Adefovir dipivoxil Combination 
monotherapy (n=18) therapy (n=28)
ALT (IU/L) 27 (14-119) 28 (13-162)
Change from baseline -145 (-1,126 to 9) -197 (-1,153 to 50)
Total bilirubin (mg/dL) 1.7 (0.6-9.2) 1.6 (0.9-5.9)
Change from baseline -1.7 (-13.4 to 5.5) -1.1 (-13.9 to 3.2)
Albumin (mg/dL) 3.4 (2.0-4.5) 3.2 (1.7-4.3)
Change from baseline 0.7 (-0.6 to 1.3) 0.4 (-0.9 to 1.3)
CPT score 7 (5-12) 7 (5-12)
Change from baseline -3 (1 to -5) -2 (1 to -6)
Improvements by ≥2  13 (72) 18 (64)
above baseline, n (%)
Higher score than  3 (17) 3 (11)
baseline, n (%)
MELD score 10 (3-23) 9 (3-20)
Change from baseline -5 (-13 to 6) -2 (-22 to 5)
Higher score than  4 (22) 5 (18)
baseline, n (%)
Serum creatinine (mg/dL) 0.9 (0.6-1.3) 0.9 (0.5-1.3)
Table 3. Biochemical and clinical responses in the patients at
week 24Adefovir Dipivoxil/lamivudine in Decompensated Chronic Hepatitis B 825
respectively (p=0.001 in monotherapy group, p<0.001 in com-
bination therapy group). However, the difference of median
reduction of CPT score between the two groups was not signif-
icant (p=0.276). 13 (72%) patients in monotherapy group and
18 (64%) in combination therapy group had CPT score im-
provement by ≥2 point from baseline at week 24. Despite
overall improvements of CPT score in both groups, 3 (17%)
patients in monotherapy group and 3 (11%) in combination
therapy group had higher CPT scores at week 24 than baseline
(Table 3). Although 2 of the 6 patients with increased CPT
scores had detectable HBV DNA levels at week 24, ALT levels
and HBV DNA levels of these patients remained lower at
week 24 than baseline (Table 2, case 2 and 6).
The median MELD score was 16 in adefovir dipivoxil mono-
therapy group and 12 in combination therapy group at base-
line, and 10 and 9 at week 24 respectively (Table 3). A signifi-
cant reduction of MELD scores was observed in each group at
week 24 (p=0.009 in monotherapy group, p<0.001 in combi-
nation therapy group) (Fig. 3). However, there was no signifi-
cant difference in median reduction of MELD score between
the two groups (p=0.405). Deterioration in MELD scores was
observed in 4 (22%) patients in monotherapy group and 5
(18%) in combination therapy group at week 24 (Table 3).
Although 3 of the 9 patients with increased MELD scores had
detectable HBV DNA level at week 24, ALT levels and
HBV DNA levels at week 24 remained lower than baseline
(Table 2, case 1, 2 and 6).
Factors associated with favorable clinical response
All the enrolled 46 patients were divided into two groups
according to the degree of improvement in CPT score. 31 pa-
tients who had improvement of ≥2 point in CTP score and
the remaining 15 patients were evaluated separately. In uni-
variate analysis, baseline ALT level was the only significant
factor associated with CPT score improvement of ≥2 point
(Table 4). Furthermore, there was a statistically significant neg-
ative correlation between baseline ALT levels and the changes
of CPT or MELD score from baseline to week 24 in the pa-
tients of both groups (correlation coefficients were -0.382 for
CPT score, p=0.009, and -0.347 for MELD score, p=0.018).
Safety
Among all 46 patients, the median creatinine levels in-
creased significantly from 0.8 mg/dL at baseline to 0.9 at week
Fig. 3. Changes of MELD score at baseline and at week 24 in adefovir dipivoxil monotherapy and adefovir dipivoxil/lamivudine combination
therapy group. There was a significant reduction of median values of MELD score at week 24 compared with baseline in both groups.
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MELD score24 (p=0.006). However, an increase in serum creatinine level
of ≥0.5 mg/dL above baseline was observed in only two pa-
tients. In one patient, serum creatinine level increased from
0.9 mg/dL at baseline to 1.4 at week 16, but adefovir dipivoxil
was continuously administered without dose reduction because
her creatinine level was still within ULN (≤1.5 mg/dL). There
was no further increase of serum creatinine level during the
24 week treatment. The other patient’s creatinine level in-
creased from 0.8 mg/dL at baseline to 1.3 at week 24. No one
developed a decreased serum phosphate level of <1.5 mg/dL.
Two patients had higher ALT levels at week 24 than their
baseline levels. One patient received adefovir dipivoxil alone,
and his CPT and MELD score were improved by 4 and 8 point
at week 24 respectively. The other received combination thera-
py, and his CPT and MELD score worsened by 1 and 5 point
at week 24 respectively. None of the elevation in ALT levels
was accompanied by detectable serum HBV DNA.
There was no death or drug-induced other serious adverse
event during the 24 weeks of treatment.
DISCUSSION
The present study indicates that both adefovir dipivoxil mo-
notherapy and adefovir dipivoxil/lamivudine combination
therapy for 24 weeks resulted in significant virologic and clini-
cal improvements in patients with decompensated liver dis-
ease and lamivudine-resistant HBV, who were not candidates
for liver transplantation. Both therapies led to marked and
rapid suppression of viral replication. At week 24, 83% of
adefovir dipivoxil monotherapy group and 86% of combina-
tion therapy group had undetectable HBV DNA level. ALT
levels normalized in 78% of adefovir dipivoxil group and 82%
of adefovir dipivoxil/lamivudine group at week 24. 72% and
64% of each group, respectively, had improvement in liver
function, as evidenced by a ≥2 point improvement in CPT
score. Furthermore, 22% and 28% of each group achieved
HBeAg loss, while HBeAg seroconversion occurred in 17%
and 21% respectively at week 24. The rate of HBeAg loss or
HBeAg seroconversion in our study is little bit higher than
those achieved in patients with compensated liver disease and
lamivudine-resistant HBV, in which only 16% of adefovir
dipivoxil group and 17% of adefovir dipivoxil/lamivudine
group were HBeAg negative and 11% and 6% of each group
achieved HBeAg seroconversion at week 48 (21). These find-
ings may be related to the high baseline ALT levels of decom-
pensated patients in our study, which is suggested in previous
studies showing that chronic hepatitis B patients with higher
pretreatment ALT levels have significantly enhanced HBeAg
seroconversion rates during lamivudine treatment (27, 28).
Our results of adefovir dipivoxil/lamivudine combination
therapy are in agreement with the findings of other uncon-
trolled studies in which the addition of adefovir dipivoxil to
lamivudine treatment were evaluated in patients with decom-
pensated chronic hepatitis B resistant to lamivudine and in
pre- and post-liver transplantation patients with active liver
disease due to lamivudine-resistant HBV respectively (22, 23).
Moreover, in the present controlled study, adefovir dipivoxil
monotherapy was as effective as adefovir dipivoxil/lamivudine
combination in suppressing viral replication. These findings
suggest that the continuation of lamivudine has no additional
or synergistic effect over adefovir dipivoxil monotherapy in
these patients, which are similar to the findings of the study
performed in patients with compensated chronic hepatitis B
and lamivudine-resistant HBV (21). Because wild-type HBV
emerges rapidly over HBV mutants after the discontinuation
of lamivudine or a switch to adefovir dipivoxil monotherapy,
the virologic responses observed in adefovir dipivoxil mono-
therapy group in our study support the findings of previous
studies that adefovir dipivoxil is active against both wild-type
and lamivudine-resistant HBV (19-21).
In patients with chronic hepatitis B with lamivudine-resis-
tant HBV, it is reported that about 16% of patients experience
ALT flares after the withdrawal of lamivudine by reversion
of wild-type HBV and 5% of patients with ALT flare expe-
rience severe acute exacerbation of chronic hepatitis B (29).
In the previous study of compensated patients with lamivu-
dine-resistant chronic hepatitis B, about one-third of patients
receiving the adefovir dipivoxil monotherapy experienced ALT
flares within 12 weeks. However, these ALT flares were not
accompanied by concurrent elevations of HBV DNA levels
and/or signs of reduced hepatic function, or even associated
with reversion to wild-type HBV (21). In the present study,
only one patient receiving adefovir monotherapy had higher
ALT level than the baseline at week 24, and undetectable HBV
DNA level and improved CTP score. However, because the
number of patients receiving adefovir dipivoxil monotherapy
was relatively small and laboratory data were recorded every
8 weeks, it is possible that the ALT flares within the eight-
week period might not be detected in our study.
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Data are expressed as median (range) without specific notation.
Patients with CPT  Patients without CPT 
score improvement score improvement
(n=31) (n=15)
Age (yr) 47 (18-67) 46 (39-67) 0.715
Sex (male:female) 23:8 13:2 0.460
Prior lamivudine  31 (8-73) 31 (15-78) 0.842
duration (months)
ALT (IU/L) 354 (60-1,168) 108 (55-380) 0.001
Total bilirubin (mg/dL) 3.2 (1.0-15.0) 2.9 (1.6-3.9) 0.156
Albumin (mg/dL) 2.8 (2.0-3.9) 2.7 (1.8-3.2) 0.084
CPT score 9 (7-12) 9 (7-11) 0.691
MELD score 13 (6-25) 12 (10-22) 0.869
HBV DNA (pg/mL) 101.5 (8-2,562) 61.0 (10.0-899.5) 0.227
Serum creatinine (mg/dL) 0.8 (0.4-1.2) 0.8 (0.5-1.3) 0.784
Table 4. Baseline characteristics of patients with or without CPT
score improvement by more than 2 points from baseline score
at week 24
pAlthough adefovir dipivoxil was effective in improving
liver function in our patients, approximately 28% of adefovir
dipivoxil monotherapy group and 36% of combination thera-
py group failed to show significant clinical responses, as evi-
denced by the improvement of CPT scores ≥2 point, despite
the overall virologic and biochemical improvement. These
observations could result from the differences in the severity
of pre-existing liver damage rather than the differences in viro-
logic response, indicating that there may be a point in the nat-
ural history of decompensated HBV infection after when the
application of antiviral therapy may be of limited benefit.
In the present study, CPT score improvement of ≥2 point
was significantly associated with higher baseline ALT levels.
Furthermore there was a significant correlation between the
baseline ALT levels and the improvement of CPT or MELD
score. This suggests that the hepatic function is more likely
to be reversible in decompensated patients with higher ne-
croinflammatory activity resulting from active viral replica-
tion. Thus, the effective suppression of the viral load by ade-
fovir dipivoxil may result in a decrease of the necroinflam-
matory activity of the liver and eventually lead to clinical
improvement.
Adefovir dipivoxil was generally well-tolerated during the
24-week treatment period in the current study, as shown in
other studies (22, 23). No patient discontinued adefovir dip-
ivoxil due to drug-related adverse events. Furthermore, there
was no development of nephrotoxicity due to adefovir dip-
ivoxil in our patients with decompensated liver disease and
normal renal function.
It can be argued that this study does not prove the efficacy
of adefovir dipivoxil because we did not include a control group
with lamivudine monotherapy matched for the severity of hep-
atic decompensation due to lamivudine-resistant HBV. How-
ever, considering the current knowledge of the poor progno-
sis of decompensated cirrhosis and diminished clinical and
virologic response of continued lamivudine monotherapy in
patients with YMDD mutant HBV (4, 13-15, 30), such an
approach would raise critical ethical concerns especially in pa-
tients with decompensated liver function due to lamivudine-
resistant HBV.
Our study has other limitations. First, the treatment period
was relatively short for only 24 weeks. However, previous expe-
riences with lamivudine therapy for decompensated HBV-cir-
rhosis have suggested that six-month survival rates with antivi-
ral treatment might be sufficient to predict substantially longer
survival rates (6, 7, 10, 11). Second, because patients were not
randomly assigned into two groups, there were slight differ-
ences in baseline characteristics such as MELD score between
the two groups. However, the differences were not statistically
significant. Finally, HBV polymerase gene mutation within
the YMDD motif was not performed in all patients.
In summary, the current study shows that a 24-week course
of adefovir dipivoxil alone or in combination with lamivudine
results in significant suppression of HBV replication, normal-
isation of ALT levels, HBeAg loss or seroconversion, and over-
all improvement in CPT and MELD score without any sig-
nificant treatment-related adverse events in decompensated
patients with lamivudine-resistant HBV. The virologic, bio-
chemical and clinical responses of the two adefovir dipivoxil
containing regimens seems to be similar suggesting that con-
tinuation of lamivudine may not confer any further benefit
over adefovir dipivoxil monotherapy in these patients. A fur-
ther study is warranted to confirm the long term effect and
safety of adefovir dipivoxil monotherapy in patients with
lamivudine-resistant decompensated chronic hepatitis B.
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